Abstract
Acquired thrombocytopenic thrombotic purpura (aTTP) is an autoantibody-mediated disease against the enzyme A Disintegrin and Metalloprotease domain with ThromboSpondin-1 type motif 13, which until now has been treated with plasma exchange (PEX) and corticosteroids. A 29-year-old female patient, who presented with aTTP in the context of pregnancy, has developed multiple relapses after treatment with PEX, corticosteroids, and rituximab. Recently, caplacizumab, a nanobody against von Willebrand factor, has been approved for the treatment of aTTP. In our patient, caplacizumab achieved better disease control, with a lower platelet count restoration time, days of PEX and hospitalization duration, as compared to standard therapy, reproducing the results of clinical trials. Caplacizumab represents a significant advance in the treatment of aTTP, especially in cases of recurrent relapses.
References
1.
Joly
BS
, Coppo
P
, Veyradier
A
. Thrombotic thrombocytopenic purpura
. Blood
. 2017
;129
(21
):2836
–46
. .2.
Kremer Hovinga
JA
, Coppo
P
, Lämmle
B
, Moake
JL
, Miyata
T
, Vanhoorelbeke
K
. Thrombotic thrombocytopenic purpura
. Nat Rev Dis Primers
. 2017
;3
:17020
. .3.
Contreras
E
, de la Rubia
J
, Del Río-Garma
J
, Díaz-Ricart
M
, García-Gala
JM
, Lozano
M
. Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group
. Med Clin
. 2015
;144
(7
):e1-331.e13
. .4.
European Medicines Agency
. Caplacizumab technical characteristics
. Madrid
: Spanish Agency of Medicines and Health Products
; 2018
.5.
Peyvandi
F
. A phase II single blind, randomized, placebo controlled trial to study the efficacy and safety of anti-von willebrand factor nanobody administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura
. Zwijnaarde: Ablynx NV
; 2011
. Protocol code: ALX-0681-2.1/10.6.
Scully
M
, Cataland
SR
, Peyvandi
F
, Coppo
P
, Knöbl
P
, Kremer Hovinga
JA
, Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
. N Engl J Med
. 2019
;380
(4
):335
–46
. .7.
Estcourt
LJ
. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)
. Transfus Med
. 2019
;29
(3
):146
–8
. .8.
Peyvandi
F
, Scully
M
, Kremer Hovinga
JA
, Knöbl
P
, Cataland
S
, De Beuf
K
, Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
. J Thromb Haemost
. 2017
;15
(7
):1448
–52
. .9.
Domingo-González
A
, Regalado-Artamendi
I
, Martín-Rojas
RM
, Pérez-Rus
G
, Pérez-Corral
A
, Díez-Martín
JL
, Application of the French TMA reference center score and the mortality in TTP score in de novo and relapsed episodes of acquired thrombotic thrombocytopenic purpura at a tertiary care facility in Spain
. J Clin Apher
. 2021
;36
:420
–28
.10.
Dutt
T
, Shaw
RJ
, Stubbs
MJ
, Yong
J
, Bailiff
B
, Cranfield
T
, Real-world Evidence of caplacizumab use in the management of acute TTP
. Blood
. 2020
;137
:1731
–40
.11.
Peyvandi
F
, Scully
M
, Kremer Hovinga
JA
, Cataland
S
, Knöbl
P
, Wu
H
, Caplacizumab for acquired thrombotic thrombocytopenic purpura
. N Engl J Med
. 2016
;374
(6
):511
–22
. .12.
Goldman
BG
, Hehir
MP
, Yambasu
S
, O’Donnell
EM
. The presentation and management of platelet disorders in pregnancy
. Eur J Haematol
. 2018
;100
(6
):560
–6
. .13.
Xu
J
, Yu
S
, Zhang
F
. Frequent recurrence of pregnancy-triggered congenital thrombotic thrombocytopenic purpura: a rare case report
. Clin Hemorheol Microcirc
. 2021
;77
(2
):195
–200
. .14.
Koranyi
J
. A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to starndard of care treatment
. Lexington
: Baxalta US Inc
; 2019
. Protocol code: SHP655-201.15.
Kaczmarek
V
, Holle
J
, Astudillo
R
, Kempf
C
, Bufler
P
, Müller
D
. Caplacizumab for relapsing thrombotic thrombocytopenic purpura
. Pediatr Nephrol
. 2019
;34
(9
):1625
–8
. .16.
Völker
LA
, Grundmann
F
, Brinkkötter
PT
. Erworbene thrombotisch-thrombozytopenische purpura: Patientenmanagement im Licht neuer Therapien
. Dtsch Med Wochenschr
. 2019
;144
(22
):1572
–5
. © 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
